On behalf of the 2016 PSOGI Planning Committee, I invite you to attend the 10th International Congress on Peritoneal Surface Malignancies taking place on November 17 -19th, 2016 in Washington, DC.
The International Congress on Peritoneal Surface Malignancies is held biannually with the first meeting taking place in London in 1998. Starting with only 14 participants, attendance has dramatically increased over the years to 500 participants at the 2014 meeting in Amsterdam.
In the past decade, the treatment of peritoneal metastases has gained interest from oncologic communities around the world. During the 1990’s, the first pioneering centers began treating patients with hyperthermic intraperitoneal chemotherapy (HIPEC). Prior to HIPEC, patients were treated with palliative support and only guaranteed a few months to live. Today, if a patient with peritoneal metastases is provided with proper treatment, the survival increases to an average of several years and improved outcomes are reported every day. The 2016 PSOGI congress’s mission is to provide clinical and scientific information on peritoneal surface malignancies and to create awareness regarding innovative treatments that will improve the quality of life for patients. The target audience includes healthcare practitioners in the field of surgical oncology, clinical oncology, gastroenterology, radiology, and gynecology. The program will also include a satellite meeting related to nurses in the field.
The 2016 International Congress on Peritoneal Surface Malignancies embraces participation from attendees and encourages interaction with faculty. We are excited to be hosting the 10th meeting in Washington, DC and look forward to your attendance.
Paul Sugarbaker, MD
PSOGI is a non-profit organization to promote research, education, and innovations in patient care regarding peritoneal metastases. The outreach is worldwide. The International Congress will bring America, Europe, Asia, and Asia Minor together regarding a common unsolved problem in gastrointestinal and gynecologic malignancy. The major goal is to implement the transfer of basic science research and clinical research to patient care. To date, major benefits to patients with gastrointestinal cancer, gynecologic malignancy, and peritoneal mesothelioma have been achieved and even more exciting improvements are expected in the near future as a result of our worldwide cooperative efforts.
2016 PSOGI Scientific Committee
CHAIR: Paul H. Sugarbaker, MD
|David Bartlett, MD
Marcello Deraco, MD
Dominique Elias, MD, PhD
Olivier Glehen, MD, PhD
Yan Li, MD, PhD
Brendan Moran, MCh, FRCS, FRCSI
|Santiago Gonzalez Moreno, MD, PhD
David Morris, MD
Pompiliu Piso, MD, PhD
Beate Rau, MBA
Vic Verwaal, MD, PhD
Yutaka Yonemura, MD, PhD
Surgical and medical oncologists, surgical oncology nurses, surgical technicians, perfusionists, and other healthcare professionals interested in peritoneal surface oncology